Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
Revolution Medicines announced updated Phase 1/2 data for RASONQUE (daraxonrasib) combined with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer, showing a 60.7% objective response rate and 12.8-month median progression-free survival in 61 patients. These positive results, which include a 76.6% twelve-month overall survival, support the ongoing Phase 3 RASolute 303 trial and come after the FDA granted Breakthrough Therapy Designation for this treatment. However, the study was open-label and identified significant dermatologic toxicity, diarrhea, stomatitis, and serious adverse reactions, including gastrointestinal perforation and interstitial lung disease.
Revolution Medicines senior advisor Stephen Kelsey sells $4.5M By Investing.com
Stephen Michael Kelsey, a Senior Advisor at Revolution Medicines, sold 27,160 shares of common stock for approximately $4.5 million on November 16, 2026, as per a pre-arranged trading plan. Prior to the sale, Kelsey exercised options to acquire the same number of shares. Despite a recent weekly decline, the stock has seen significant annual and year-to-date gains, and analysts maintain "Buy" ratings, with the company also reporting strong product revenue following the launch and European approval of RASONQUE.
Form 4 Revolution Medicines Inc: Stephen Michael Kelsey (Officer) For: 16 November
This article reports on a Form 4 filing for Revolution Medicines Inc, specifically noting a transaction by officer Stephen Michael Kelsey on November 16. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of securities by a company's officers, directors, and major shareholders. The article is brief and provides no further details beyond the filing's existence and the parties involved.
Form 4 Revolution Medicines Inc: Stephen Michael Kelsey (Officer) For: 16 November
This article reports on a Form 4 filing by Revolution Medicines Inc, detailing an insider transaction involving Stephen Michael Kelsey, an officer of the company, for November 16. The brief report highlights the filing related to the company's stock, RVMD, and includes a link to view comments.
Revolution Medicines Received the California Life Sciences Pantheon Award for Biopharma Product of the Year
Revolution Medicines was honored with the California Life Sciences (CLS) Pantheon Award for Biopharma Product of the Year. Adrian Gill, Executive Vice President, accepted the award, highlighting the company's dedication to challenging assumptions about RAS-driven cancers and thanking patients, families, and clinical trial partners. The award acknowledges the collaborative efforts of the company and the broader California biotech community.
Form 4 Revolution Medicines Inc: Flavia Borellini (Director) For: 13 November
This article reports on a Form 4 filing for Revolution Medicines Inc, indicating an insider transaction by Flavia Borellini, a Director, on November 13. The filing details are relevant for investors tracking insider activity, which can sometimes signal management's confidence in the company's prospects. Revolution Medicines Inc. (RVMD) is noted with a stock change of -1.37%.
The European Commission Approves Revolution Medicines' Daraxonrasib for Metastatic Pancreatic Cancer
The European Commission has approved Revolution Medicines' Daraxonrasib, a once-daily oral monotherapy, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. This decision introduces a new RAS-targeted treatment option, addressing a significant unmet medical need in patients with or without an identified tumor RAS mutation. The approval is based on positive results from the phase 3 RASolute 302 trial, which demonstrated improved overall survival and progression-free survival compared to chemotherapy.
Form 4 Revolution Medicines Inc: Flavia Borellini (Director) For: 13 November By Investing.com
This article reports on a Form 4 filing for Revolution Medicines Inc, indicating an insider transaction by Director Flavia Borellini on November 13th. The brief news item also mentions the stock symbol RVMD, which saw a -2.50% change.
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The European Commission has approved Revolution Medicines' RASONQUE (daraxonrasib) for treating adult patients with metastatic pancreatic adenocarcinoma who have received prior systemic therapy. This marks the first broad RAS-targeted medicine approved in Europe for this aggressive cancer, including patients with or without a RAS tumor mutation. The approval is based on positive results from the Phase 3 RASolute 302 clinical trial, which demonstrated significant survival benefits.
After selling 92,531 shares, an officer proposes another sale at Revolution Medicines (RVMD).
Revolution Medicines (RVMD) officer Stephen Kelsey has proposed to sell 108,640 common shares valued at approximately $18.7 million, with an approximate sale date of November 16, 2026. These shares are expected to be acquired through stock-option exercises. This proposed sale follows previous sales by Kelsey in September 2026, totaling over 98,000 shares.
Form 144 REVOLUTION MEDICINES INC For: 16 November By Investing.com
This article announces the filing of Form 144 for REVOLUTION MEDICINES INC (RVMD) on November 16, 2026. Form 144 is a notice of the intent to sell restricted securities. The article provides the company's stock symbol and its current performance.
Form 144 REVOLUTION MEDICINES INC For: 16 November By Investing.com
This article reports on a Form 144 filing for Revolution Medicines Inc. (RVMD) on November 16. It notes that the stock experienced a -2.50% change and provides a static snapshot of various market indices and commodities. The article reiterates the filing information multiple times without additional details about the form's content.
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The European Commission has approved Revolution Medicines' RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have undergone at least one prior systemic therapy. This marks the first broad RAS-targeted medicine for this condition, regardless of an identified RAS tumor mutation. While a significant step, actual patient access in the EU is contingent on country-specific pricing and reimbursement processes, and the drug carries a risk of significant side effects, including dermatologic toxicity and serious adverse reactions.
Form 144 Revolution Medicines For: 14 November By Investing.com
This article from Investing.com announces a Form 144 filing for Revolution Medicines, relating to November 14th. The filing is brief and primarily serves as a notification regarding insider transactions for the company, identified by the stock symbol RVMD, which saw a -2.30% change.
Alexis Borisy gifts 10,625 Revolution Medicines (RVMD) shares to a charitable donor advised fund.
Alexis Borisy, a director at Revolution Medicines, Inc. (RVMD), reported gifting 10,625 common shares to a charitable donor advised fund on November 11, 2026, for no consideration. Following this transaction, his direct holdings in the company amount to 2,329,450 shares, which include 1,191 restricted stock units. This bona fide gift was detailed in a Form 4 SEC filing.
Form 4 Revolution Medicines Inc: Alexis Borisy (Director) For: 11 November By Investing.com
This article reports on a Form 4 filing for Revolution Medicines Inc, detailing insider transactions by director Alexis Borisy. The filing is for activity on November 11th. The piece primarily serves as a notification of this regulatory document, offering no further analysis.
Form 4 Revolution Medicines Inc: Jack Anders (CFO) For: 11 November
This article reports on a Form 4 filing for Revolution Medicines Inc, indicating that Chief Financial Officer Jack Anders made a transaction on November 11. The brief piece also notes the current stock performance of Revolution Medicines Inc (RVMD), showing a slight decrease.
CFO exercises $18.56 and $42.45 options and sells shares at Revolution Medicines (RVMD).
Revolution Medicines' CFO, Jack Anders, exercised vested options on November 11, 2026, acquiring 15,900 shares at $42.45 and 19,850 shares at $18.56. On the same day, he sold a total of 35,750 common shares in 11 transactions, with prices ranging from $181.0421 to $192.8406 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted in August 2026.
An officer sold 35,750 Revolution Medicines (RVMD) shares under a preset trading plan.
Jack Lee Anders, an officer at Revolution Medicines, Inc. (RVMD), reported selling 35,750 common shares worth $6,901,895 on November 11, 2026, under a Rule 10b5-1 trading plan. He also sold 4,053 shares in the preceding three months for $807,513.37. These transactions were officially filed with the SEC on November 12, 2026, after acquiring the shares through stock option exercise.
Revolution Medicines officer sells $162,200 in shares
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc. (NASDAQ:RVMD), sold 811 shares of company stock for $162,200, while simultaneously exercising stock options to acquire an equal number of shares. These transactions were conducted under a pre-arranged trading plan. Despite the stock trading above its Fair Value, 18 analysts have revised their earnings upwards for the upcoming period.
After exercising options, Revolution Medicines (RVMD) officer sells 811 shares at $200 each.
Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc. (RVMD), recently exercised options to acquire 811 common shares and subsequently sold all 811 shares at $200 per share. These transactions, executed on November 9, 2026, were conducted under a Rule 10b5-1 trading plan adopted in June 2026. After these transactions, Mancini directly holds 39,765 common shares and 116,704 stock options.
What Sent Revolution Medicines Stock Lower?
Revolution Medicines (RVMD) stock dropped 6.4% on November 11, 2026, despite a broader market rise, with many biotechnology peers increasing. The decline occurred after an earnings call revealed that initial sales of its new cancer drug, Daraxonrasib, were boosted by finite patient groups and initial inventory stocking, making the normalized launch trajectory unclear. The stock's valuation remains high at 196.6 times sales, and its operating loss widened in the third quarter.
Revolution Medicines (RVMD) Stock Dropped, So What Is Driving Attention Now?
Revolution Medicines (RVMD) is gaining attention after its drug Rasonque received US approval and a positive EU opinion for metastatic pancreatic adenocarcinoma, focusing investors on its RAS-focused pipeline. Despite recent stock drops of 6.4% in one day and 9.5% over the past week, RVMD still shows a strong year-to-date return of 128.7%. Analysts currently consider RVMD 30.9% undervalued with a fair value of $261.47, highlighting the potential from its targeted oncology treatments and ongoing Phase III trials, though risks include trial setbacks and high operating expenses.
Form 4 Revolution Medicines Inc For: 7 November By Investing.com
This article reports on a Form 4 filing for Revolution Medicines Inc (RVMD) on November 7, 2026. Form 4 filings are regulatory documents that disclose changes in ownership of company securities by insiders. The article notes that RVMD's stock was up 8.24%.
Revolution Medicines (RVMD) Rallies On RASONQUE Launch As Fair Value Debate Heats Up
Revolution Medicines (RVMD) is seeing increased investor attention after its third-quarter earnings report, which showed significant revenue driven by the RASONQUE launch. While the stock has seen short-term fluctuations, its year-to-date and one-year returns are strongly positive, leading to a debate among analysts about its fair value, with some seeing it as undervalued based on long-term growth prospects and others noting potential risks in late-stage trials.
Revolution Medicines Announces FDA Approval of RAS(ON) Inhibitor and Q3 2026 Progress
Revolution Medicines has announced the FDA approval and launch of its RAS(ON) multi-selective inhibitor for eligible adults with previously treated metastatic pancreatic cancer. The company also reported its Q3 2026 financial results and corporate progress, including advancements in clinical development for pancreatic, lung, and colorectal cancers, and preparations for international approvals.
What Just Happened To Revolution Medicines Stock?
Revolution Medicines (RVMD) stock rose 8.2% on November 6, 2026, following an 11.0% fall after reporting its Q3 2026 results. This marked the company's first quarter as a commercial-stage entity, with its pancreatic cancer drug Rasonque generating $198 million in net product revenue. Despite the recent gain, the stock ended the week below its November 4 close and traded at 209.2 times its trailing sales, significantly higher than the S&P 500.
Revolution Medicines Stock Gets A Lift From Pancreatic Cancer Drug Launch
Revolution Medicines (RVMD) reported US$197.56 million in Q3 2026 revenue, solely from the early U.S. launch of its pancreatic cancer drug, RASONQUE, which quickly gained preferred status and treated over 5,000 patients. Despite significant revenue, the company posted substantial net losses, with the rapid uptake of RASONQUE being a crucial near-term catalyst. The investment narrative hinges on the RAS(ON) franchise evolving beyond research into a commercial success, supported by a US$3.7 billion liquidity buffer to fund ongoing Phase 3 programs.
Revolution Medicines Shares Rise About 6% After Q3 Results Beat
Revolution Medicines saw its shares climb approximately 6% in after-hours trading after reporting third-quarter results that exceeded revenue and earnings expectations. The oncology drug developer reaffirmed its 2026 GAAP operating expense forecast of $2.1 billion to $2.2 billion, while posting a GAAP loss of $1.90 per share for the quarter.
Revolution’s Rasonque off to best cancer drug launch ‘in history’
Revolution Medicines' new pancreatic cancer drug, Rasonque, has achieved an "unprecedented" launch, generating $198 million in sales in just five weeks, far exceeding analyst expectations. Despite its high price of $39,800 for a 30-day supply, most insurers are covering the drug, and analysts are significantly raising revenue forecasts for the coming years. However, company executives caution that it's still too early to draw long-term conclusions, especially as the initial sales included a transition from an early access program.
RevMed’s Rasonque debut nets ‘eye-popping’ $198M in 5 weeks, even as exec tempers expectations
Revolution Medicines' new RAS inhibitor, Rasonque (daraxonrasib), achieved "eye-popping" initial sales of $197.6 million in just five weeks after its August 26 approval, significantly exceeding analyst expectations. Despite this strong performance, RevMed leadership is cautiously optimistic, noting that initial sales were boosted by temporary factors like expanded access switches and patients awaiting therapy. The drug is now being prepared for launch in the European Union and Japan following regulatory approvals.
RevMed’s Rasonque shatters analyst estimates with $198M quarter
Revolution Medicines (RevMed) significantly exceeded analyst expectations with its new pancreatic cancer therapy, Rasonque, reporting $198 million in revenue from just five weeks of sales. This remarkable launch, driven by pent-up demand and effective patient transition strategies, has reached over 5,000 patients. Analysts are bullish on Rasonque's growth potential, with revised Q4 sales estimates and ongoing efforts to expand global availability and develop the drug for additional indications.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines has reported an "eye-popping and jaw-dropping" commercial debut for its pancreatic cancer drug, Rasonque, generating $198 million in sales in just five weeks following its U.S. approval. Over 5,000 patients have already been treated with the groundbreaking pan-RAS inhibitor. This sales performance nearly doubled even the most optimistic investor estimates, positioning Rasonque as potentially one of the best cancer drug launches in history.
This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time’
Revolution Medicines' new pancreatic cancer drug, Rasonque, is experiencing an exceptionally strong launch, with third-quarter sales of $198 million far exceeding analyst estimates. Jefferies projects the drug could reach $3.1 billion in sales next year, making it potentially "one of the best oncology launches of all time." This early success follows its FDA approval in late August.
Revolution Medicines Q3FY26 Results: Net loss widens to $407.5 million
Revolution Medicines reported a widened net loss of $407.5 million in Q3 2026, up from $305.2 million year-over-year, primarily due to increased R&D and SG&A expenses following the FDA approval of RASONQ. Despite the loss, the company generated $197.6 million in net product revenue during its first five weeks of RASONQ commercialization, treating over 5,000 patients. The company ended the quarter with a strong cash position of $3.7 billion, with additional Phase 3 studies advancing and Breakthrough Therapy designation received for daraxonrasib.
Revolution Medicines Q3 2026 Earnings Call Transcript
Revolution Medicines reported strong third-quarter 2026 financial results, with RASONQ generating $197.6 million in net product revenue after its FDA approval on August 26, primarily for metastatic pancreatic cancer. The company emphasized its rapid U.S. launch execution, broad physician engagement, and encouraging early payer access, while also progressing with international expansion plans and advancing multiple Phase 3 studies for its RAS(ON) inhibitor portfolio in various cancers. With $3.7 billion in cash, Revolution Medicines plans increased operating expenses in 2027 to support its growing pipeline and global commercialization efforts.
Revolution Medicines Reports Nearly $198M in Rasonque Sales After Five Weeks on US Market
Revolution Medicines reported impressive sales of nearly $198 million for its drug Rasonque in the third quarter, despite only being on the US market for five weeks. This strong performance indicates a successful launch for the pharmaceutical company's new product.
Why Did Revolution Medicines (RVMD) Move Today?
Revolution Medicines (RVMD) saw a significant stock movement today due to FDA approval of Rasonque for metastatic pancreatic adenocarcinoma, following strong Phase 3 data. Despite a recent cool-down in momentum, the stock has posted impressive year-to-date and one-year returns. Analysts currently peg the company as 25% undervalued, citing its RAS(ON) portfolio and ongoing registrational trials as potential long-term growth drivers.
Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week
This article identifies 10 stocks with market caps of at least $25 billion that are expected to experience implied price swings of over 10% after their earnings reports this week, according to Benzinga Pro data. The focus is on tech mega caps like Apple, AMD, and Qualcomm, but the biggest expected swings are elsewhere. The list includes companies such as Coupang, Revolution Medicines, Cloudflare, Natera, Lumentum, Datadog, Medline, Coherent, AppLovin, and Moderna, detailing their expected earnings, recent performance, and analyst actions.
Vanguard reports a passive stake above 5% in Revolution Medicines (RVMD).
Vanguard Capital Management has reported a passive beneficial ownership stake of 5.13% in Revolution Medicines, Inc. (RVMD), totaling 10,999,044 common shares. This position includes securities held by various Vanguard funds and client accounts, with Vanguard retaining sole voting power over 1,849,510 shares and sole dispositive power over all 10,999,044 shares. The SEC filing, a Schedule 13G, indicates that this acquisition is in the ordinary course of business and not for the purpose of influencing company control.
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
Medicilon honored Revolution Medicines with the "Excellence in Client Partnership Award" for its pioneering work in pan-KRAS drug discovery and development, including the FDA approval of Daraxonrasib for metastatic pancreatic cancer. The award recognizes a three-year collaboration built on mutual trust and shared R&D success. Both companies held discussions to explore new collaboration opportunities and enhance cross-border R&D efficiency.
Should Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?
Revolution Medicines (RVMD) has reported new data from its Phase 3 RASolute 302 trial and received a positive EMA CHMP opinion for RASONQUE, strengthening its RAS targeted therapy for pancreatic cancer. This progress supports a broader opportunity for RASONQUE, but the company still faces execution risks related to pricing, uptake, and managing significant operating expenses and an extensive late-stage pipeline. Investors are evaluating how this development impacts the company's long-term financial projections and potential for dilution.
Revolution Medicines officer sells $431,946 in shares
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (NASDAQ:RVMD), sold shares worth $431,946 and acquired shares totaling $77,662 through an option exercise on October 26, 2026. These transactions, executed under a 10b5-1 trading plan, occurred as the company's stock surged 224% over the past year, though InvestingPro analysis indicates it may be overvalued. Analysts from UBS, Truist Securities, Guggenheim, William Blair, and Brookline Capital Markets have recently reiterated or initiated positive ratings for Revolution Medicines, citing promising trial results and a focus on RAS-targeted therapies.
Revolution Medicines (RVMD) officer exercised options at $33.62 and sold shares at $186.99.
Revolution Medicines' Chief Global Commercialization Officer, Anthony Mancini, exercised options to acquire 2,310 common shares at $33.62 and subsequently sold all 2,310 shares at $186.99 on October 26, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2026. Following these transactions, Mancini holds 91,315 stock options and 39,765 common shares directly.
Revolution Medicines to Participate in November 2026 Investor Conferences
Revolution Medicines, Inc. announced that its CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in two investor conferences in November 2026: the 3rd Annual Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. The company, focused on RAS-addicted cancers, will provide live and archived webcasts of these events on its investor relations website.
Revolution Medicines (RVMD) Could Be 28% Undervalued As RASONQUE News Lifts Its Story
Revolution Medicines (RVMD) is considered 28% undervalued with a fair value of $257.47, against a last close of $186.22, following new Phase 3 RASolute 302 trial data and a positive CHMP opinion for RASONQUE. The company's RAS oncology platform, targeting high unmet need tumors, is central to its long-term revenue growth potential. Despite strong year-to-date performance, the stock's P/B ratio indicates a rich entry point, suggesting investors are paying a premium ahead of substantial revenues.
Lightning Round: Penguin Solutions and Revolution Medicines
Jim Cramer of "Mad Money" offers his insights on two stocks, Penguin Solutions and Revolution Medicines, during the show's "Lightning Round." The article features a video clip where Cramer provides his expert opinion on these companies.
Revolution Medicines’ CEO has two November fireside chats scheduled.
Revolution Medicines (RVMD) announced that CEO and Chairman Mark A. Goldsmith will participate in two investor conferences in November 2026. He is scheduled to speak at the Guggenheim Healthcare Innovation Conference on November 10 and the Jefferies Global Healthcare Conference on November 16. Webcasts and replays of these events will be available on the company's website.
Revolution Medicines director sells $1.96 million of stock
Elizabeth M. Anderson, a director at Revolution Medicines, Inc. (NASDAQ:RVMD), sold 10,143 shares of the company's common stock worth approximately $1.96 million on September 22, 2026. This transaction occurred after Anderson exercised stock options to acquire 5,070 shares and was conducted under a pre-arranged 10b5-1 trading plan. The sale follows a significant 217% return for the stock over the past year, though InvestingPro analysis suggests it is currently overvalued.
ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
Incyte believes its KRAS G12D inhibitor, INCB161734, is a strong contender against Revolution Medicines' zoldonrasib in the pancreatic cancer space, with early phase 1 data showing promising response rates. The company presented data at ESMO 2026, highlighting an 81% confirmed objective response rate for INCB161734 combined with modified FOLFIRINOX in pancreatic ductal adenocarcinoma patients. Incyte is moving forward with global phase 3 trials and sees this asset, along with others, as crucial for its future growth beyond its blockbuster Jakafi.